Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson’s Disease
Parkinson’s Disease (PD) is a neurological disease characterized by the progressive degeneration of the nigrostriatal dopaminergic pathway with consequent loss of neurons in the substantia nigra pars compacta and dopamine depletion. The cytoplasmic inclusions of α-synuclein (α-Syn), known as Lewy bo...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-07-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/13/4766 |
| _version_ | 1797563301031313408 |
|---|---|
| author | Giovanni Schepici Serena Silvestro Placido Bramanti Emanuela Mazzon |
| author_facet | Giovanni Schepici Serena Silvestro Placido Bramanti Emanuela Mazzon |
| author_sort | Giovanni Schepici |
| collection | DOAJ |
| description | Parkinson’s Disease (PD) is a neurological disease characterized by the progressive degeneration of the nigrostriatal dopaminergic pathway with consequent loss of neurons in the substantia nigra pars compacta and dopamine depletion. The cytoplasmic inclusions of α-synuclein (α-Syn), known as Lewy bodies, are the cytologic hallmark of PD. The presence of α-Syn aggregates causes mitochondrial degeneration, responsible for the increase in oxidative stress and consequent neurodegeneration. PD is a progressive disease that shows a complicated pathogenesis. The current therapies are used to alleviate the symptoms of the disease without changing its clinical course. Recently, phytocompounds with neuroprotective effects and antioxidant properties such as caffeine have aroused the interest of researchers. The purpose of this review is to summarize the preclinical studies present in the literature and clinical trials recorded in ClinicalTrial.gov, aimed at illustrating the effects of caffeine used as a nutraceutical compound combined with the current PD therapies. Therefore, the preventive effects of caffeine in the neurodegeneration of dopaminergic neurons encourage the use of this alkaloid as a supplement to reduce the progress of the PD. |
| first_indexed | 2024-03-10T18:40:41Z |
| format | Article |
| id | doaj.art-8f9aa0f366ef4db48d788b5971db4eed |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T18:40:41Z |
| publishDate | 2020-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-8f9aa0f366ef4db48d788b5971db4eed2023-11-20T05:52:05ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-07-012113476610.3390/ijms21134766Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson’s DiseaseGiovanni Schepici0Serena Silvestro1Placido Bramanti2Emanuela Mazzon3IRCCS Centro Neurolesi “Bonino-Pulejo”, Via Provinciale Palermo, Contrada Casazza, 98124 Messina, ItalyIRCCS Centro Neurolesi “Bonino-Pulejo”, Via Provinciale Palermo, Contrada Casazza, 98124 Messina, ItalyIRCCS Centro Neurolesi “Bonino-Pulejo”, Via Provinciale Palermo, Contrada Casazza, 98124 Messina, ItalyIRCCS Centro Neurolesi “Bonino-Pulejo”, Via Provinciale Palermo, Contrada Casazza, 98124 Messina, ItalyParkinson’s Disease (PD) is a neurological disease characterized by the progressive degeneration of the nigrostriatal dopaminergic pathway with consequent loss of neurons in the substantia nigra pars compacta and dopamine depletion. The cytoplasmic inclusions of α-synuclein (α-Syn), known as Lewy bodies, are the cytologic hallmark of PD. The presence of α-Syn aggregates causes mitochondrial degeneration, responsible for the increase in oxidative stress and consequent neurodegeneration. PD is a progressive disease that shows a complicated pathogenesis. The current therapies are used to alleviate the symptoms of the disease without changing its clinical course. Recently, phytocompounds with neuroprotective effects and antioxidant properties such as caffeine have aroused the interest of researchers. The purpose of this review is to summarize the preclinical studies present in the literature and clinical trials recorded in ClinicalTrial.gov, aimed at illustrating the effects of caffeine used as a nutraceutical compound combined with the current PD therapies. Therefore, the preventive effects of caffeine in the neurodegeneration of dopaminergic neurons encourage the use of this alkaloid as a supplement to reduce the progress of the PD.https://www.mdpi.com/1422-0067/21/13/4766caffeineParkinson’s Diseaseexperimental modelsneuroprotective effectsclinical trials |
| spellingShingle | Giovanni Schepici Serena Silvestro Placido Bramanti Emanuela Mazzon Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson’s Disease International Journal of Molecular Sciences caffeine Parkinson’s Disease experimental models neuroprotective effects clinical trials |
| title | Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson’s Disease |
| title_full | Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson’s Disease |
| title_fullStr | Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson’s Disease |
| title_full_unstemmed | Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson’s Disease |
| title_short | Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson’s Disease |
| title_sort | caffeine an overview of its beneficial effects in experimental models and clinical trials of parkinson s disease |
| topic | caffeine Parkinson’s Disease experimental models neuroprotective effects clinical trials |
| url | https://www.mdpi.com/1422-0067/21/13/4766 |
| work_keys_str_mv | AT giovannischepici caffeineanoverviewofitsbeneficialeffectsinexperimentalmodelsandclinicaltrialsofparkinsonsdisease AT serenasilvestro caffeineanoverviewofitsbeneficialeffectsinexperimentalmodelsandclinicaltrialsofparkinsonsdisease AT placidobramanti caffeineanoverviewofitsbeneficialeffectsinexperimentalmodelsandclinicaltrialsofparkinsonsdisease AT emanuelamazzon caffeineanoverviewofitsbeneficialeffectsinexperimentalmodelsandclinicaltrialsofparkinsonsdisease |